CD73 Biomarker Selection for NSCLC Combination Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Non-small-cell lung cancer (NSCLC) is relatively insensitive to chemotherapy, leading to low survival rates and a need for improved therapeutic approaches, particularly for advanced stages.
Innovation Solution
The use of CD73 and PD1/PD-L1 antagonists in combination, determined by the level of CD73 in a subject's sample, to identify and treat NSCLC patients likely to benefit from this treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy is used to treat NSCLC, then cancer cells are targeted, but survival rates remain low and treatment effectiveness is insufficient
Solution Approach 1:
The patent combines CD73 antagonist therapy with PD1/PD-L1 antagonist therapy to treat NSCLC. This combination approach addresses the limitation of single-agent chemotherapy by integrating two mechanisms of action: CD73 inhibition to block adenosine-mediated immune suppression and PD1/PD-L1 inhibition to enhance T-cell anti-tumor activity, thereby improving both treatment effectiveness and survival rates
Solution Approach 2:
The patent uses CD73 expression level as a predictive biomarker to identify patients who are likely to respond to the combination therapy. By measuring and utilizing this parameter to select appropriate patients, the treatment approach optimizes its effectiveness for the target population, addressing the contradiction between treatment reliability and survival improvement
2Measurement precision
If targeted agents are used to address specific genetic aberrations, then treatment precision is improved, but not all patients benefit and treatment options remain limited
Solution Approach 1:
The patent employs CD73 expression level as a measurable parameter to predict treatment response. This biomarker-based approach enables precise identification of patients who are likely to benefit from combination therapy, providing treatment precision while expanding adaptability by offering a targeted solution for a specific patient subset that current treatments cannot effectively address
Solution Approach 2:
CD73 serves as an intermediary biomarker that mediates between the patient's tumor characteristics and the treatment decision. By using CD73 expression levels as this intermediary measure, the system bridges the gap between available treatment options and patient-specific needs, enabling more adaptable and precise treatment selection
Data Source
AI summary
Biomarkers and methods for the treatment of non-small cell lung cancer (NSCLC). Biomarkers for patient selection and prognosis, and diagnostic kit for analyzing the biomarkers.